Jump to main content
Jump to site search

Issue 6, 2009
Previous Article Next Article

Expanding proteomics into the analysis of chiral drugs

Author affiliations

Abstract

The chiralities of chiral drugs have been investigated extensively with the purpose of enlightening the role of chirality in drug action. Proteomics, though in its infancy, has recently emerged as the foremost technology in drug development research, possessing the advantage of providing more useful information about an organism than genomics, as it directly addresses the level of genome products and their interactions. In this review, we will discuss the background of chiral drug investigation from which contemporary drug chirality research has emerged, the techniques involved in proteomics technology, the application of proteomics in this exciting area, and the perspectives in future applications of this field.

Graphical abstract: Expanding proteomics into the analysis of chiral drugs

Back to tab navigation

Publication details

The article was received on 25 Feb 2009, accepted on 01 Apr 2009 and first published on 28 Apr 2009


Article type: Review Article
DOI: 10.1039/B903858B
Citation: Mol. BioSyst., 2009,5, 603-608
  •   Request permissions

    Expanding proteomics into the analysis of chiral drugs

    J. Sui, J. Zhang, C. B. Ching and W. N. Chen, Mol. BioSyst., 2009, 5, 603
    DOI: 10.1039/B903858B

Search articles by author

Spotlight

Advertisements